Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 6, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 8, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002081169-26-000002
Filed / recorded
Jan 8, 2026, 11:45 PM UTC
Added to OQRO
Oct 6, 2026, 4:40 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
Issuer CIK
879407
Ticker
ARWR
Reporting person
Daniel Joseph Apel
Relationship
Officer
Officer title
Chief Financial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jan 6, 2026
Transaction code
A
Shares / units
75,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
176,200
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents shares underlying restricted stock units which will vest in four equal annual installments.
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.